This pipeline uses various statistical tests to identify miRs whose log2 expression levels correlated to selected clinical features.
Testing the association between 461 miRs and 11 clinical features across 492 samples, statistically thresholded by P value < 0.05 and Q value < 0.3, 9 clinical features related to at least one miRs.
-
10 miRs correlated to 'Time to Death'.
-
HSA-MIR-34B , HSA-MIR-34C , HSA-MIR-627 , HSA-MIR-450A-2 , HSA-MIR-130B , ...
-
3 miRs correlated to 'AGE'.
-
HSA-MIR-590 , HSA-MIR-148A , HSA-MIR-29B-2
-
54 miRs correlated to 'NEOPLASM.DISEASESTAGE'.
-
HSA-MIR-139 , HSA-MIR-625 , HSA-MIR-486 , HSA-MIR-21 , HSA-MIR-155 , ...
-
57 miRs correlated to 'PATHOLOGY.T.STAGE'.
-
HSA-MIR-139 , HSA-MIR-486 , HSA-MIR-625 , HSA-MIR-21 , HSA-MIR-155 , ...
-
3 miRs correlated to 'PATHOLOGY.N.STAGE'.
-
HSA-MIR-193A , HSA-MIR-99B , HSA-MIR-34C
-
55 miRs correlated to 'PATHOLOGY.M.STAGE'.
-
HSA-MIR-144 , HSA-MIR-625 , HSA-MIR-130B , HSA-MIR-106B , HSA-MIR-155 , ...
-
20 miRs correlated to 'GENDER'.
-
HSA-MIR-100 , HSA-MIR-708 , HSA-MIR-455 , HSA-MIR-599 , HSA-MIR-204 , ...
-
23 miRs correlated to 'RACE'.
-
HSA-MIR-26B , HSA-MIR-497 , HSA-MIR-3605 , HSA-MIR-195 , HSA-MIR-590 , ...
-
1 miR correlated to 'ETHNICITY'.
-
HSA-MIR-219-2
-
No miRs correlated to 'KARNOFSKY.PERFORMANCE.SCORE', and 'NUMBERPACKYEARSSMOKED'.
Complete statistical result table is provided in Supplement Table 1
Table 1. Get Full Table This table shows the clinical features, statistical methods used, and the number of miRs that are significantly associated with each clinical feature at P value < 0.05 and Q value < 0.3.
Clinical feature | Statistical test | Significant miRs | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=10 | shorter survival | N=10 | longer survival | N=0 |
AGE | Spearman correlation test | N=3 | older | N=3 | younger | N=0 |
NEOPLASM DISEASESTAGE | Kruskal-Wallis test | N=54 | ||||
PATHOLOGY T STAGE | Spearman correlation test | N=57 | higher stage | N=43 | lower stage | N=14 |
PATHOLOGY N STAGE | Wilcoxon test | N=3 | class1 | N=3 | class0 | N=0 |
PATHOLOGY M STAGE | Kruskal-Wallis test | N=55 | ||||
GENDER | Wilcoxon test | N=20 | male | N=20 | female | N=0 |
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=0 | ||||
NUMBERPACKYEARSSMOKED | Spearman correlation test | N=0 | ||||
RACE | Kruskal-Wallis test | N=23 | ||||
ETHNICITY | Wilcoxon test | N=1 | not hispanic or latino | N=1 | hispanic or latino | N=0 |
Table S1. Basic characteristics of clinical feature: 'Time to Death'
Time to Death | Duration (Years) | 7-3668 (median=1321.5) |
censored | N = 327 | |
death | N = 25 | |
Significant markers | N = 10 | |
associated with shorter survival | 10 | |
associated with longer survival | 0 |
Table S2. Get Full Table List of 10 miRs significantly associated with 'Time to Death' by Cox regression test
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
HSA-MIR-34B | 1.5 | 1.244e-06 | 0.00057 | 0.754 |
HSA-MIR-34C | 1.43 | 7.22e-06 | 0.0033 | 0.673 |
HSA-MIR-627 | 2.1 | 0.0001124 | 0.052 | 0.732 |
HSA-MIR-450A-2 | 1.99 | 0.0001193 | 0.055 | 0.697 |
HSA-MIR-130B | 2.9 | 0.000125 | 0.057 | 0.666 |
HSA-MIR-149 | 1.75 | 0.0001289 | 0.059 | 0.736 |
HSA-MIR-450A-1 | 1.92 | 0.0002392 | 0.11 | 0.693 |
HSA-MIR-9-1 | 1.29 | 0.0002585 | 0.12 | 0.663 |
HSA-MIR-9-2 | 1.28 | 0.0003541 | 0.16 | 0.65 |
HSA-MIR-296 | 1.86 | 0.0004447 | 0.2 | 0.7 |
Table S3. Basic characteristics of clinical feature: 'AGE'
AGE | Mean (SD) | 60.56 (12) |
Significant markers | N = 3 | |
pos. correlated | 3 | |
neg. correlated | 0 |
Table S4. Get Full Table List of 3 miRs significantly correlated to 'AGE' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-590 | 0.1807 | 5.558e-05 | 0.0256 |
HSA-MIR-148A | 0.1599 | 0.0003709 | 0.171 |
HSA-MIR-29B-2 | 0.1585 | 0.0004185 | 0.192 |
Table S5. Basic characteristics of clinical feature: 'NEOPLASM.DISEASESTAGE'
NEOPLASM.DISEASESTAGE | Labels | N |
STAGE I | 234 | |
STAGE II | 54 | |
STAGE III | 125 | |
STAGE IV | 79 | |
Significant markers | N = 54 |
Table S6. Get Full Table List of top 10 miRs differentially expressed by 'NEOPLASM.DISEASESTAGE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-139 | 9.203e-13 | 4.24e-10 |
HSA-MIR-625 | 1.412e-09 | 6.5e-07 |
HSA-MIR-486 | 4.915e-09 | 2.26e-06 |
HSA-MIR-21 | 1.929e-08 | 8.83e-06 |
HSA-MIR-155 | 2.05e-08 | 9.37e-06 |
HSA-LET-7I | 3.104e-08 | 1.42e-05 |
HSA-MIR-144 | 4.244e-08 | 1.93e-05 |
HSA-MIR-130B | 7.412e-08 | 3.37e-05 |
HSA-MIR-106B | 2.519e-07 | 0.000114 |
HSA-MIR-451 | 5.557e-07 | 0.000251 |
Table S7. Basic characteristics of clinical feature: 'PATHOLOGY.T.STAGE'
PATHOLOGY.T.STAGE | Mean (SD) | 1.91 (0.96) |
N | ||
1 | 240 | |
2 | 65 | |
3 | 176 | |
4 | 11 | |
Significant markers | N = 57 | |
pos. correlated | 43 | |
neg. correlated | 14 |
Table S8. Get Full Table List of top 10 miRs significantly correlated to 'PATHOLOGY.T.STAGE' by Spearman correlation test
SpearmanCorr | corrP | Q | |
---|---|---|---|
HSA-MIR-139 | -0.3304 | 5.431e-14 | 2.5e-11 |
HSA-MIR-486 | -0.273 | 7.437e-10 | 3.42e-07 |
HSA-MIR-625 | 0.2686 | 1.406e-09 | 6.45e-07 |
HSA-MIR-21 | 0.2615 | 3.884e-09 | 1.78e-06 |
HSA-MIR-155 | 0.2493 | 2.097e-08 | 9.58e-06 |
HSA-MIR-144 | -0.2424 | 5.221e-08 | 2.38e-05 |
HSA-MIR-9-1 | 0.2343 | 1.456e-07 | 6.62e-05 |
HSA-MIR-130B | 0.2339 | 1.537e-07 | 6.98e-05 |
HSA-MIR-451 | -0.2319 | 1.98e-07 | 8.97e-05 |
HSA-MIR-9-2 | 0.2251 | 4.55e-07 | 0.000206 |
Table S9. Basic characteristics of clinical feature: 'PATHOLOGY.N.STAGE'
PATHOLOGY.N.STAGE | Labels | N |
class0 | 224 | |
class1 | 18 | |
Significant markers | N = 3 | |
Higher in class1 | 3 | |
Higher in class0 | 0 |
Table S10. Get Full Table List of 3 miRs differentially expressed by 'PATHOLOGY.N.STAGE'
W(pos if higher in 'class1') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-193A | 3020 | 0.0004449 | 0.205 | 0.749 |
HSA-MIR-99B | 1030 | 0.0005628 | 0.258 | 0.7445 |
HSA-MIR-34C | 2613 | 0.0006293 | 0.288 | 0.7498 |
Table S11. Basic characteristics of clinical feature: 'PATHOLOGY.M.STAGE'
PATHOLOGY.M.STAGE | Labels | N |
M0 | 405 | |
M1 | 78 | |
MX | 8 | |
Significant markers | N = 55 |
Table S12. Get Full Table List of top 10 miRs differentially expressed by 'PATHOLOGY.M.STAGE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-144 | 7.905e-07 | 0.000364 |
HSA-MIR-625 | 8.534e-07 | 0.000393 |
HSA-MIR-130B | 1.648e-06 | 0.000756 |
HSA-MIR-106B | 3.533e-06 | 0.00162 |
HSA-MIR-155 | 4.052e-06 | 0.00185 |
HSA-MIR-1277 | 5.3e-06 | 0.00242 |
HSA-MIR-10B | 5.558e-06 | 0.00253 |
HSA-MIR-186 | 6.204e-06 | 0.00282 |
HSA-LET-7I | 9.752e-06 | 0.00442 |
HSA-MIR-1269 | 1.424e-05 | 0.00644 |
Table S13. Basic characteristics of clinical feature: 'GENDER'
GENDER | Labels | N |
FEMALE | 169 | |
MALE | 323 | |
Significant markers | N = 20 | |
Higher in MALE | 20 | |
Higher in FEMALE | 0 |
Table S14. Get Full Table List of top 10 miRs differentially expressed by 'GENDER'. 0 significant gene(s) located in sex chromosomes is(are) filtered out.
W(pos if higher in 'MALE') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-100 | 39354 | 8.064e-16 | 3.72e-13 | 0.7209 |
HSA-MIR-708 | 36180 | 2.961e-09 | 1.36e-06 | 0.6628 |
HSA-MIR-455 | 19155 | 5.502e-08 | 2.53e-05 | 0.6491 |
HSA-MIR-599 | 6842 | 1.053e-07 | 4.82e-05 | 0.6805 |
HSA-MIR-204 | 19906 | 1.014e-06 | 0.000463 | 0.6342 |
HSA-MIR-31 | 28290 | 6.125e-06 | 0.00279 | 0.6308 |
HSA-MIR-155 | 33793 | 1.426e-05 | 0.00649 | 0.6191 |
HSA-MIR-30A | 21385 | 7.975e-05 | 0.0362 | 0.6082 |
HSA-MIR-500B | 21569 | 0.0001597 | 0.0723 | 0.6036 |
HSA-MIR-500A | 21824 | 0.0002602 | 0.118 | 0.6002 |
No miR related to 'KARNOFSKY.PERFORMANCE.SCORE'.
Table S15. Basic characteristics of clinical feature: 'KARNOFSKY.PERFORMANCE.SCORE'
KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 88.33 (23) |
Score | N | |
0 | 2 | |
70 | 1 | |
80 | 3 | |
90 | 13 | |
100 | 17 | |
Significant markers | N = 0 |
Table S16. Basic characteristics of clinical feature: 'NUMBERPACKYEARSSMOKED'
NUMBERPACKYEARSSMOKED | Mean (SD) | 29 (15) |
Value | N | |
7 | 1 | |
10 | 1 | |
30 | 2 | |
40 | 2 | |
46 | 1 | |
Significant markers | N = 0 |
Table S17. Basic characteristics of clinical feature: 'RACE'
RACE | Labels | N |
ASIAN | 8 | |
BLACK OR AFRICAN AMERICAN | 32 | |
WHITE | 445 | |
Significant markers | N = 23 |
Table S18. Get Full Table List of top 10 miRs differentially expressed by 'RACE'
ANOVA_P | Q | |
---|---|---|
HSA-MIR-26B | 1.923e-06 | 0.000887 |
HSA-MIR-497 | 3.561e-06 | 0.00164 |
HSA-MIR-3605 | 3.687e-06 | 0.00169 |
HSA-MIR-195 | 3.84e-06 | 0.00176 |
HSA-MIR-590 | 1.168e-05 | 0.00534 |
HSA-MIR-1271 | 2.021e-05 | 0.00921 |
HSA-MIR-186 | 2.244e-05 | 0.0102 |
HSA-MIR-574 | 2.772e-05 | 0.0126 |
HSA-MIR-3613 | 3.815e-05 | 0.0173 |
HSA-MIR-424 | 4.663e-05 | 0.0211 |
Table S19. Basic characteristics of clinical feature: 'ETHNICITY'
ETHNICITY | Labels | N |
HISPANIC OR LATINO | 22 | |
NOT HISPANIC OR LATINO | 324 | |
Significant markers | N = 1 | |
Higher in NOT HISPANIC OR LATINO | 1 | |
Higher in HISPANIC OR LATINO | 0 |
Table S20. Get Full Table List of one miR differentially expressed by 'ETHNICITY'
W(pos if higher in 'NOT HISPANIC OR LATINO') | wilcoxontestP | Q | AUC | |
---|---|---|---|---|
HSA-MIR-219-2 | c("117", "0.0002285") | c("117", "0.0002285") | 0.105 | 0.8892 |
-
Expresson data file = KIRC-TP.miRseq_RPKM_log2.txt
-
Clinical data file = KIRC-TP.merged_data.txt
-
Number of patients = 492
-
Number of miRs = 461
-
Number of clinical features = 11
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.